Ashutosh Kumar Arya Selected Research

Parathyroid Neoplasms (Parathyroid Neoplasm)

1/2022	Aberrant Epigenetic Alteration of PAX1 Expression Contributes to Parathyroid Tumorigenesis.
9/2021	Parathyroid Carcinoma: An Experience from the Indian Primary Hyperparathyroidism Registry.
3/2021	Progressive rise in the prevalence of asymptomatic primary hyperparathyroidism in India: Data from PHPT registry.
1/2021	GCM2 Silencing in Parathyroid Adenoma Is Associated With Promoter Hypermethylation and Gain of Methylation on Histone 3.
1/2020	Reduced Calcium Sensing Receptor (CaSR) Expression Is Epigenetically Deregulated in Parathyroid Adenomas.
12/2019	Minimally invasive parathyroid carcinoma-A missing entity between parathyroid adenoma and carcinoma: Scintigraphic and histological features.
1/2017	Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas.
10/2014	Changes in parathyroid proteome in patients with primary hyperparathyroidism due to sporadic parathyroid adenomas.
10/2013	Methylation status of the CpG islands in vitamin D and calcium-sensing receptor gene promoters does not explain the reduced gene expressions in parathyroid adenomas.
7/2013	Simultaneous expression analysis of vitamin D receptor, calcium-sensing receptor, cyclin D1, and PTH in symptomatic primary hyperparathyroidism in Asian Indians.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ashutosh Kumar Arya Research Topics

Disease

10	Parathyroid Neoplasms (Parathyroid Neoplasm) 01/2022 - 07/2013
7	Primary Hyperparathyroidism 01/2022 - 07/2013
3	Adenoma (Adenomas) 01/2020 - 07/2013
2	Pancreatitis 01/2022 - 12/2018
2	Neoplasm Metastasis (Metastasis) 09/2021 - 12/2019
2	Carcinogenesis 01/2021 - 01/2020
1	Neoplasms (Cancer) 01/2022
1	Nephrolithiasis 01/2022
1	Disease Progression 09/2021
1	Vitamin D Deficiency 07/2021
1	Hyperplasia 01/2019
1	Hypercalcemia (Milk Alkali Syndrome) 01/2019
1	Hyperparathyroidism 01/2019
1	Pain (Aches) 12/2018
1	Fatigue 12/2018
1	Postmenopausal Osteoporosis 06/2017
1	Bone Resorption 06/2017
1	Anemia 09/2015

Drug/Important Bio-Agent (IBA)

9	Parathyroid Hormone (Parathormone)IBA 01/2022 - 07/2013
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2014
3	Messenger RNA (mRNA)IBA 01/2022 - 07/2013
3	CalciumIBA 09/2021 - 12/2018
3	Alkaline PhosphataseIBA 07/2021 - 12/2018
3	Calcium-Sensing ReceptorsIBA 01/2020 - 07/2013
2	hydrogen sulfite (bisulfite)IBA 01/2022 - 10/2013
2	ChromatinIBA 01/2022 - 01/2020
2	CreatinineIBA 01/2022 - 12/2018
2	Histones (Histone)IBA 01/2022 - 01/2021
2	isoprocarbIBA 09/2021 - 12/2019
2	Cyclin D1IBA 01/2017 - 07/2013
2	Calcitriol Receptors (Calcitriol Receptor)IBA 10/2013 - 07/2013
1	Lysine (L-Lysine)FDA Link 01/2022
1	Peptides (Polypeptides)IBA 01/2019
1	Technetium (Technetium 99m)IBA 12/2018
1	Phosphates (Orthophosphate)IBA 12/2018
1	calcium phosphateIBA 12/2018
1	Technetium Tc 99m Sestamibi (Cardiolite)FDA LinkGeneric 12/2018
1	Amylases FDA Link 12/2018
1	25-hydroxyvitamin DIBA 12/2018
1	hydroxide ionIBA 12/2018
1	Teriparatide (Parathar)FDA Link 06/2017
1	Collagen Type I (Type I Collagen)IBA 06/2017
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2017
1	Protein Isoforms (Isoforms)IBA 01/2017
1	ProteomeIBA 10/2014
1	Vitamin D FDA LinkGeneric 10/2013
1	DNA (Deoxyribonucleic Acid)IBA 10/2013

Therapy/Procedure

3	Parathyroidectomy 01/2021 - 09/2015
2	Therapeutics 01/2021 - 06/2017